NCT07269886Completed
BIOMARKERS FOR DRUG SELECTION IN DEPRESSION
BIOMARKERS FOR DRUG SELECTION IN DEPRESSION: 3BD Test
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
The study aims to assess whether providing Clinical Decision Support Software (CDSS) information improves the pharmacological response in patients with depression. The CDSS integrates genomic, clinical, and blood biomarker data to assist psychiatrists in selecting the most appropriate treatment for each patient. A total of 72 patients diagnosed with Major Depressive Disorder were recruited. Participants were male and female adults aged 18 to 65 years, all presenting with moderate to severe symptomatology as assessed by the HAM-D-17 scale. Enrolled patients were randomized into two groups: * TAU group (Treatment as Usual) (+): patients received standard clinical care. * CDSS group: psychiatrists received and could incorporate CDSS-generated information when making treatment decisions. (+) The TAU group received CDSS information at the 12-week follow-up. All patients underwent blood collection at baseline (for blood-based and genomic biomarkers) and completed clinical evaluations at baseline, and at 8, 12, and 24 weeks of follow-up.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 79 (actual)
- First submitted
- 21 Nov 2025
- Start date
- 18 Aug 2022
- Primary completion date
- 16 Oct 2022
- Lead sponsor
- Neomente SAS
- Diseases
- Depression
- NCT number
- NCT07269886
What you commit to
- Study type: Observational
- Participants enrolled: 79
- From 18 Aug 2022 to the primary completion date, 16 Oct 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Having a current or past diagnosis of bipolar disorder or psychotic disorders.
- Having a moderate to severe substance use disorder within the past six months.
- Having a neurocognitive disorder.
- Having an unstable or decompensated medical illness likely to confound study outcomes.
Other
- Having active suicidal ideation.
- Being pregnant or lactating.
- Having known contraindications to the indicated antidepressant classes.
- Being unable to provide informed consent.
- \-
Who the study is looking for
- Being male or female, aged 18-65.
- Having a current DSM-5 diagnosis of non-psychotic Major Depressive Disorder confirmed by SCID.
- Having moderate to severe depressive symptoms as measured by the HAM-D-17.
- Being indicated for pharmacotherapy for Major Depressive Disorder.
- Providing written informed consent (signed and dated).
- \-
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neomente Coordinator of this site? Confirm its status | Buenos Aires | Argentina | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.